Dmitry I Gabrilovich

List of Publications by Year in Descending Order

208 papers	45,168 citations	87 h-index	212 g-index
218 ext. papers	53,153 ext. citations	11.9 avg, IF	8.1 L-index

#	Paper	IF	Citations
208	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts.. *Journal of Cancer*, **2022**, 13, 1933-1944	4.5	1
207	Myeloid-Derived Suppressor Cells and Radiotherapy.. *Cancer Immunology Research*, **2022**, OF1-OF13	12.5	4
206	Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models. *Methods in Molecular Biology*, **2021**, 2236, 19-28	1.4	2
205	Myeloid-cell derived oxidized lipids and regulation of the tumor microenvironment. *Cancer Research*, **2021**,	10.1	2
204	Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. *Cancer Discovery*, **2021**, 11, 2693-2706	24.4	12
203	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. *Nature Communications*, **2021**, 12, 6023	17.4	1
202	Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. *Nature Communications*, **2021**, 12, 1717	17.4	15
201	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. *Clinical Cancer Research*, **2021**, 27, 1019-1028	12.9	14
200	Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. *Cancer Research*, **2021**, 81, 658-670	10.1	7
199	EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. *Science Advances*, **2021**, 7,	14.3	10
198	Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. *IScience*, **2021**, 24, 102016	6.1	5
197	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. *Nature Communications*, **2021**, 12, 346	17.4	34
196	Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nature Reviews Immunology*, **2021**, 21, 485-498	36.5	180
195	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. *Journal of Experimental Medicine*, **2021**, 218,	16.6	36
194	Upregulation of C/EBP□Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. *Clinical Cancer Research*, **2021**, 27, 5961-5978	12.9	5
193	The Dawn of Myeloid-Derived Suppressor Cells: Identification of Arginase I as the Mechanism of Immune Suppression. *Cancer Research*, **2021**, 81, 3953-3955	10.1	2
192	Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. *Journal of Clinical Investigation*, **2021**, 131,	15.9	7

191	Activation of p38δ stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. *Nature Cancer*, **2020**, 1, 603-619	15.4	8
190	Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men. *Biomarker Insights*, **2020**, 15, 1177271920913320	3.5	2
189	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. *Cancer Discovery*, **2020**, 10, 1282-1295	24.4	29
188	Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. *Nature Chemical Biology*, **2020**, 16, 278-290	11.7	105
187	PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. *JCI Insight*, **2020**, 5,	9.9	16
186	Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. *JCI Insight*, **2020**, 5,	9.9	34
185	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. *Journal of Clinical Investigation*, **2020**, 130, 2789-2799	15.9	13
184	Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1929-1936	7.4	21
183	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. *Cell Reports*, **2020**, 33, 108571	10.6	26
182	A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors. *Cancer Research*, **2020**, 80, 5270-5281	10.1	8
181	Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. *Science Translational Medicine*, **2020**, 12,	17.5	36
180	All Myeloid-Derived Suppressor Cells Are Not Created Equal: How Gender Inequality Influences These Cells and Affects Cancer Therapy. *Cancer Discovery*, **2020**, 10, 1100-1102	24.4	3
179	BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. *Science*, **2020**, 369, 942-949	33.3	33
178	MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer. *Cancer Research*, **2019**, 79, 6215-6226	10.1	18
177	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. *Journal of Experimental Medicine*, **2019**, 216, 2150-2169	16.6	43
176	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. *Molecular and Cellular Biology*, **2019**, 39,	4.8	16
175	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. *Journal of Biological Chemistry*, **2019**, 294, 10407-10414	5.4	16
174	Fatty acid transport protein 2 reprograms neutrophils in cancer. *Nature*, **2019**, 569, 73-78	50.4	215

173	Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6286-6291	11.5	21
172	"Redox lipidomics technology: Looking for a needle in a haystack". *Chemistry and Physics of Lipids*, **2019**, 221, 93-107	3.7	26
171	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. *Clinical Cancer Research*, **2019**, 25, 2783-2794	12.9	18
170	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. *Cancer Research*, **2019**, 79, 5482-5489	10.1	55
169	Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice. *Journal of Clinical Investigation*, **2019**, 129, 4261-4275	15.9	29
168	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. *Cancer Immunology, Immunotherapy*, **2019**, 68, 517-527	7.4	18
167	The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 243-246	10.2	48
166	Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. *Journal of Cell Biology*, **2018**, 217, 1739-1755	7.3	29
165	Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature Medicine*, **2018**, 24, 541-550	50.5	1772
164	Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. *Cancer Immunology Research*, **2018**, 6, 696-710	12.5	13
163	Myeloid-derived suppressor cells coming of age. *Nature Immunology*, **2018**, 19, 108-119	19.1	805
162	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. *Seminars in Immunology*, **2018**, 35, 19-28	10.7	135
161	Biology of Myeloid-Derived Suppressor Cells **2018**, 181-197		2
160	Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. *Nature Medicine*, **2018**, 24, 224-231	50.5	98
159	Plasticity of myeloid-derived suppressor cells in cancer. *Current Opinion in Immunology*, **2018**, 51, 76-82	7.8	175
158	"Only a Life Lived for Others Is Worth Living": Redox Signaling by Oxygenated Phospholipids in Cell Fate Decisions. *Antioxidants and Redox Signaling*, **2018**, 29, 1333-1358	8.4	20
157	ICAM-1 controls development and function of ILC2. *Journal of Experimental Medicine*, **2018**, 215, 2157-2174	12.6	34
156	Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. *Cancer Research*, **2018**, 78, 5644-5655	10.1	24

155	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. *Clinical Cancer Research*, **2018**, 24, 5347-5356	12.9	140
154	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. *Cancer Research*, **2018**, 78, 4215-4228	10.1	31
153	Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. *Journal of Clinical Investigation*, **2018**, 128, 5095-5109	15.9	66
152	CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. *JCI Insight* , **2018**, 3,	9.9	40
151	Unique pattern of neutrophil migration and function during tumor progression. *Nature Immunology* , **2018**, 19, 1236-1247	19.1	77
150	ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence and Repopulation of Hematopoietic Stem Cells. *Stem Cell Reports*, **2018**, 11, 258-273	8	24
149	Dendritic cells in cancer: the role revisited. *Current Opinion in Immunology*, **2017**, 45, 43-51	7.8	226
148	Myeloid-Derived Suppressor Cells. *Cancer Immunology Research*, **2017**, 5, 3-8	12.5	833
147	Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. *Clinical Cancer Research*, **2017**, 23, 2942-2950	12.9	96
146	Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. *Nature Communications*, **2017**, 8, 2122	17.4	100
145	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. *Cancer Cell*, **2017**, 32, 654-668.e5	24.3	293
144	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. *Clinical Cancer Research*, **2017**, 23, 5187-5201	12.9	211
143	Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. *OncoTargets and Therapy*, **2017**, 10, 4239-4250	4.4	29
142	Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. *Journal of Clinical Investigation*, **2017**, 127, 3755-3769	15.9	28
141	A Bayesian pick-the-winner design in a randomized phase II clinical trial. *Oncotarget*, **2017**, 8, 88376-88385	5.3	2
140	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. *Science Immunology*, **2016**, 1,	28	378
139	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, **2016**, 7, 12150	17.4	1388
138	CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. *Immunity*, **2016**, 44, 303-15	32.3	227

137	The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. *Trends in Immunology*, **2016**, 37, 208-220	14.4	1056
136	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. *Cancer Letters*, **2016**, 371, 117-24	9.9	44
135	1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. *Oncotarget*, **2016**, 7, 52618-52630	3.3	5
134	A neuronal network of mitochondrial dynamics regulates metastasis. *Nature Communications*, **2016**, 7, 13730	17.4	80
133	Fatal attraction: How macrophages participate in tumor metastases. *Journal of Experimental Medicine*, **2015**, 212, 976	16.6	2
132	ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells. *Cancer Cell*, **2015**, 28, 147-9	24.3	14
131	Transcriptional regulation of myeloid-derived suppressor cells. *Journal of Leukocyte Biology*, **2015**, 98, 913-22	6.5	188
130	Regulation of tumor metastasis by myeloid-derived suppressor cells. *Annual Review of Medicine*, **2015**, 66, 97-110	17.4	310
129	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. *Molecular Immunology*, **2015**, 63, 579-85	4.3	75
128	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood*, **2015**, 126, 1621-8	2.2	82
127	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
126	Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. *Journal of Experimental Medicine*, **2015**, 212, 351-67	16.6	53
125	Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. *Journal of Clinical Investigation*, **2015**, 125, 3356-64	15.9	660
124	Effects of notch signaling on regulation of myeloid cell differentiation in cancer. *Cancer Research*, **2014**, 74, 141-52	10.1	68
123	Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. *Immunology and Cell Biology*, **2014**, 92, 200-3	5	10
122	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology*, **2014**, 143, 512-9	7.8	202
121	Molecular speciation and dynamics of oxidized triacylglycerols in lipid droplets: Mass spectrometry and coarse-grained simulations. *Free Radical Biology and Medicine*, **2014**, 76, 53-60	7.8	20
120	Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?. *Immunity*, **2014**, 41, 341-343	3.3	10

119	Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. *Cancer Immunology, Immunotherapy*, **2014**, 63, 1009-21	7.4	28
118	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
117	Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCΠ abundance. *Science Signaling*, **2014**, 7, ra16	8.8	34
116	Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. *Journal of Immunology*, **2014**, 192, 2920-31	5.3	142
115	Myeloid-derived suppressor cells in the development of lung cancer. *Cancer Immunology Research*, **2014**, 2, 50-8	12.5	75
114	COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse. *Blood*, **2014**, 124, 1610-21	2.2	16
113	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. *Journal of Clinical Investigation*, **2014**, 124, 2626-39	15.9	209
112	A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma. *Blood*, **2014**, 124, 5729-5729	2.2	2
111	Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 405-10	7.4	65
110	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 909-18	7.4	215
109	Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. *Journal of Immunology*, **2013**, 190, 3815-23	5.3	146
108	Reciprocal relationship between myeloid-derived suppressor cells and T cells. *Journal of Immunology*, **2013**, 191, 17-23	5.3	132
107	History of myeloid-derived suppressor cells. *Nature Reviews Cancer*, **2013**, 13, 739-52	31.3	793
106	Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. *Nature Immunology*, **2013**, 14, 211-20	19.1	252
105	Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 692-702	4.7	56
104	Applying pressure on macrophages. *Immunity*, **2013**, 38, 205-6	32.3	2
103	Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis. *Journal of Immunology*, **2013**, 191, 1916-26	5.3	14
102	The role of mannose-6-phosphate receptor and autophagy in influencing the outcome of combination therapy. *Autophagy*, **2013**, 9, 615-6	10.2	8

101	Induction of myelodysplasia by myeloid-derived suppressor cells. *Journal of Clinical Investigation*, **2013**, 123, 4595-611	15.9	187
100	Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. *Seminars in Cancer Biology*, **2012**, 22, 282-8	12.7	53
99	Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. *Immunotherapy*, **2012**, 4, 373-82	3.8	28
98	Coordinated regulation of myeloid cells by tumours. *Nature Reviews Immunology*, **2012**, 12, 253-68	36.5	2405
97	Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. *Cancer Research*, **2012**, 72, 5483-93	10.1	58
96	Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 924-32	4	92
95	Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. *Journal of Leukocyte Biology*, **2012**, 91, 167-81	6.5	362
94	Recent Advances in Immunotherapy of Lung Cancer. *Journal of Lung Cancer*, **2012**, 11, 1		1
93	Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. *Cancer Research*, **2012**, 72, 928-38	10.1	84
92	Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. *Cancer Immunology, Immunotherapy*, **2012**, 61, 573-9	7.4	21
91	Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. *Clinical Cancer Research*, **2012**, 18, 4877-82	12.9	87
90	Cellular immunotherapy for soft tissue sarcomas. *Immunotherapy*, **2012**, 4, 283-90	3.8	11
89	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. *Blood*, **2012**, 120, 4728-4728	2.2	
88	Accumulation of Myeloid-Derived Suppressor Cells in Bone Marrow in Multiple Myeloma Induces Tumor-Specific Immune Suppression and Promotes Tumor Growth. *Blood*, **2012**, 120, 3954-3954	2.2	
87	Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.. *Blood*, **2012**, 120, 2999-2999	2.2	
86	Mass-spectrometric characterization of peroxidized and hydrolyzed lipids in plasma and dendritic cells of tumor-bearing animals. *Biochemical and Biophysical Research Communications*, **2011**, 413, 149-53	3.4	12
85	Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends in Immunology*, **2011**, 32, 19-25	14.4	573
84	Highlights of 10 years of immunology in Nature Reviews Immunology. *Nature Reviews Immunology*, **2011**, 11, 693-702	36.5	75

83	Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. *Laboratory Investigation*, **2011**, 91, 598-608	5.9	92
82	Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. *Cancer Immunology, Immunotherapy*, **2011**, 60, 419-23	7.4	41
81	Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. *Journal of Clinical Investigation*, **2011**, 121, 4015-29	15.9	252
80	Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC). *Blood*, **2011**, 118, 788-788	2.2	5
79	Lipid accumulation and dendritic cell dysfunction in cancer. *Nature Medicine*, **2010**, 16, 880-6	50.5	386
78	Regulation of dendritic cell differentiation and function by Notch and Wnt pathways. *Immunological Reviews*, **2010**, 234, 105-19	11.3	46
77	Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. *Journal of Clinical Investigation*, **2010**, 120, 1111-24	15.9	333
76	HIF-1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. *Journal of Experimental Medicine*, **2010**, 207, 2439-53	16.6	783
75	Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. *Journal of Immunology*, **2010**, 184, 3106-16	5.3	306
74	Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. *Clinical Cancer Research*, **2010**, 16, 1812-23	12.9	225
73	Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. *Molecular Cancer Therapeutics*, **2010**, 9, 3200-9	6.1	36
72	Myeloid-derived suppressor cells in human cancer. *Cancer Journal (Sudbury, Mass)*, **2010**, 16, 348-53	2.2	184
71	Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. *Journal of Immunotherapy*, **2010**, 33, 817-27	5	37
70	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. *Expert Opinion on Biological Therapy*, **2010**, 10, 983-91	5.4	83
69	The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. *European Journal of Immunology*, **2010**, 40, 2969-75	6.1	436
68	Myeloid-derived suppressor cells as regulators of the immune system. *Nature Reviews Immunology*, **2009**, 9, 162-74	36.5	4599
67	Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. *Immunity*, **2009**, 30, 845-59	32.3	84
66	Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. *Journal of Immunology*, **2009**, 182, 5693-701	5.3	552

65	Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).. *Blood*, **2009**, 114, 597-597	2.2	4
64	Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. *Drug Resistance Updates*, **2008**, 11, 210-8	23.2	24
63	Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. *Journal of Experimental Medicine*, **2008**, 205, 2235-49	16.6	685
62	Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *Journal of Immunology*, **2008**, 181, 5791-802	5.3	1289
61	Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. *Journal of Clinical Oncology*, **2008**, 26, 3235-41	2.2	170
60	Tumor escape mechanism governed by myeloid-derived suppressor cells. *Cancer Research*, **2008**, 68, 2561-3	13.1	264
59	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. *Blood*, **2008**, 111, 2220-9	2.2	159
58	Combined modality immunotherapy and chemotherapy: a new perspective. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1523-9	7.4	59
57	Notch signaling in differentiation and function of dendritic cells. *Immunologic Research*, **2008**, 41, 1-14	4.3	38
56	Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy. *Blood*, **2008**, 112, 4653-4653	2.2	
55	Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. *Nature Medicine*, **2007**, 13, 828-35	50.5	816
54	The terminology issue for myeloid-derived suppressor cells. *Cancer Research*, **2007**, 67, 425; author reply 426	10.1	519
53	Targeting of Jak/STAT pathway in antigen presenting cells in cancer. *Current Cancer Drug Targets*, **2007**, 7, 71-7	2.8	43
52	Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. *Clinical Cancer Research*, **2007**, 13, 4840-8	12.9	163
51	Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. *Cancer Research*, **2007**, 67, 11021-8	10.1	299
50	Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. *Blood*, **2007**, 109, 507-15	2.2	71
49	Comment on "Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells". *Journal of Immunology*, **2007**, 178, 4705-6; author reply 4706	5.3	5
48	MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *Journal of Experimental Medicine*, **2007**, 204, 1463-74	16.6	507

47	Immunosuppressive strategies that are mediated by tumor cells. *Annual Review of Immunology*, **2007**, 25, 267-96	34.7	1260
46	Role of immature myeloid cells in mechanisms of immune evasion in cancer. *Cancer Immunology, Immunotherapy*, **2006**, 55, 237-45	7.4	294
45	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 878-87	12.9	336
44	All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. *Cancer Research*, **2006**, 66, 9299-307	10.1	462
43	INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. *Expert Opinion on Biological Therapy*, **2006**, 6, 823-32	5.4	48
42	Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. *Cancer and Metastasis Reviews*, **2006**, 25, 323-31	9.6	143
41	A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.. *Blood*, **2006**, 108, 841-841	2.2	
40	Developing dendritic cells become RacyPcells packed with fat and glycogen. *Immunology*, **2005**, 115, 473-88	7	34
39	Rational design of shepherdin, a novel anticancer agent. *Cancer Cell*, **2005**, 7, 457-68	24.3	275
38	Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. *Journal of Immunology*, **2005**, 175, 4338-46	5.3	166
37	Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. *Cancer Research*, **2005**, 65, 9525-35	10.1	244
36	Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. *Journal of Immunology*, **2005**, 175, 4583-92	5.3	256
35	STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. *Journal of Immunology*, **2005**, 174, 4880-91	5.3	339
34	Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. *Journal of Immunology*, **2004**, 172, 464-74	5.3	349
33	Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. *Journal of Immunology*, **2004**, 172, 989-99	5.3	652
32	Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. *Blood*, **2004**, 103, 3503-10	2.2	229
31	Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. *Nature Medicine*, **2004**, 10, 48-54	50.5	911
30	Mechanisms and functional significance of tumour-induced dendritic-cell defects. *Nature Reviews Immunology*, **2004**, 4, 941-52	36.5	832

29	Immune tolerance in breast cancer. *Breast Disease*, **2004**, 20, 93-103	1.6	15
28	Tumor escape from immune response: mechanisms and targets of activity. *Current Drug Targets*, **2003**, 4, 525-36	3	61
27	VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. *Blood* , **2003**, 101, 4878-86	2.2	387
26	Notch signaling is necessary but not sufficient for differentiation of dendritic cells. *Blood*, **2003**, 102, 3980-8	2.2	80
25	Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. *Journal of Leukocyte Biology*, **2003**, 74, 186-96	6.5	212
24	Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. *Clinical Cancer Research*, **2003**, 9, 285-94	12.9	76
23	Development of vaccines against self-antigens: the p53 paradigm. *Current Opinion in Drug Discovery & Development*, **2003**, 6, 169-73		5
22	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. *Cancer Research*, **2003**, 63, 4441-9	10.1	326
21	Full-length dominant-negative survivin for cancer immunotherapy. *Clinical Cancer Research*, **2003**, 9, 6523-33	12.9	72
20	Immature myeloid cells and cancer-associated immune suppression. *Cancer Immunology, Immunotherapy*, **2002**, 51, 293-8	7.4	258
19	H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. *Journal of Leukocyte Biology*, **2002**, 72, 285-96	6.5	34
18	Dendritic cell vaccines for cancer treatment. *Current Opinion in Molecular Therapeutics*, **2002**, 4, 452-8		23
17	Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. *International Journal of Cancer*, **2001**, 94, 825-33	7.5	121
16	Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. *Journal of Immunology*, **2001**, 166, 5398-406	5.3	438
15	Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. *Journal of Immunology*, **2001**, 167, 4458-67	5.3	194
14	Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. *Journal of Virology*, **2001**, 75, 7621-8	6.6	57
13	Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. *Human Immunology*, **2001**, 62, 332-41	2.3	70
12	Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. *Journal of Immunology*, **2001**, 166, 678-89	5.3	1072

11	Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. *Clinical and Experimental Metastasis*, **1999**, 17, 881-8	4.7	38
10	Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo. *Blood*, **1998**, 92, 4150-4166	2.2	788
9	Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. *Human Gene Therapy*, **1997**, 8, 187-93	4.8	70
8	Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. *Cellular Immunology*, **1996**, 170, 101-10	4.4	199
7	Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. *Cellular Immunology*, **1996**, 170, 111-9	4.4	188
6	Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. *International Journal of Cancer*, **1996**, 67, 756-63	7.5	45
5	A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. *Nature Genetics*, **1996**, 13, 210-3	36.3	166
4	Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nature Medicine*, **1996**, 2, 1096-103	50.5	1495
3	Murine retrovirus induces defects in the function of dendritic cells at early stages of infection. *Cellular Immunology*, **1994**, 158, 167-81	4.4	20
2	Clinical significance of neutrophil functional activity in HIV infection. *Scandinavian Journal of Infectious Diseases*, **1994**, 26, 41-7		21
1	Effects of murine leukemia viruses on the function of dendritic cells. *European Journal of Immunology*, **1993**, 23, 2932-8	6.1	9